Approximately 15 percent of men who have normal PSA readings, are determined to have prostate cancer. This finding appears in the New England Journal of Medicine (May 27, 2004) and is based on a study of 2,950 men. A PSA test (prostate-specific antigen) measures biomarkers in the blood that can be an indication of cancer.

According to Dr. Arthur Centeno, co-author of Prostate Cancer--A Patient's Guide to Treatment, "We have know for years that PSA is not the most sensitive indicator for the detection of prostate cancer; however, at present it is the best test available. Science is working on other tests, some of which look at the DNA found in cells from the urine and blood, to predict the need for biopsy." A tissue biopsy is a more accurate detector of prostate cancer.

Dr. Centeno points out that the PSA has saved many lives. "With the widespread use of PSA for the past twelve to fourteen years, we have been able to decrease the mortality rates of this disease, when compared to the Scandinavian countries, which do not use the PSA test."

Dr. Centeno and his co-author, Dr. Gary Onik, discuss PSA as a diagnostic tool in Prostate Cancer--A Patient's Guide to Treatment. They also discuss other diagnostic tools such as the digital rectal exam, transrectal ultrasound, needle biopsy, and a 3D global mapping biopsy.

In addition to covering how prostate cancer is diagnosed, the book covers treatments for the disease, including: surgery, radiation, cryotherapy, chemotherapy, and hormonal therapy. The book also discusses coping emotionally, overcoming impotence, and the importance of emotional support after a cancer diagnosis.

Dr. Arthur Centeno is a urologist with Urology San Antonio in Texas. Dr. Gary Onik, a radiologist, is the director of surgical imaging at Celebration Health Florida Hospital in Orlando.